Albumin change predicts failure in ulcerative colitis treated with adalimumab

• Published in: PloS one Vol. 19; no. 1; p. e0295681
• Main Authors: Ishida, Natsuki, Takahashi, Kenichi, Asai, Yusuke, Miyazu, Takahiro, Tamura, Satoshi, Tani, Shinya, Yamade, Mihoko, Iwaizumi, Moriya, Hamaya, Yasushi, Osawa, Satoshi, Sugimoto, Ken
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 02.01.2024; Public Library of Science (PLoS)
• Subjects: Adalimumab; Adalimumab - therapeutic use; Albumin; Analysis; Antibodies; Biological products; Biology and Life Sciences; Colitis, Ulcerative - drug therapy; Colitis, Ulcerative - pathology; Dosage and administration; Drug therapy; Endoscopy; Failure; Health aspects; Hospitals; Humans; Inflammatory bowel disease; Infliximab; Measurement; Medical colleges; Medical prognosis; Medicine and Health Sciences; Monoclonal antibodies; Patient compliance; Patient outcomes; Patients; Pharmacology; Prognosis; Remission (Medicine); Retrospective Studies; Serum Albumin; Treatment Failure; Treatment Outcome; Tumor necrosis factor; Tumor necrosis factor-TNF; Tumor necrosis factor-α; Ulcerative colitis; Japan; Taiwan
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0295681

Anti-tumor necrosis factor (TNF) -α antibodies, including infliximab (IFX), adalimumab (ADA), and golimumab, which were the first biologic therapeutic agents, have a crucial position in advanced therapy for ulcerative colitis (UC). We aimed to investigate serum albumin (Alb) change as a prognostic factor for the therapeutic effect of ADA in UC. Thirty-four patients with UC treated with ADA were enrolled in this study and were divided into failure and non-failure groups. Biological data, such as Alb were compared between the two groups. Thirteen patients showed failure within six months. Examination of the biological data showed a significant difference between the two groups only in the week 2/week 0 Alb ratio. In receiver-operating characteristic (ROC) curve analysis to predict failure, the cut-off value of week 2/week 0 Alb ratio was 1.00, and the area under the curve was 0.868 (95% confidence interval: 0.738-0.999). In addition, in the sub-group analysis of only clinically active patients, the week 2/week 0 Alb ratio of the non-failure group was significantly higher than that of the failure group, and the cut-off-value in ROC analysis was 1.00. Week 2/week 0 Alb ratio ≤ 1 predicts failure within six months of ADA for UC.